NEJM October 2026

Small-cell lung cancer after relapse: tambotatug pelitecan in the TAISHAN-302 trial

If small-cell lung cancer comes back or keeps growing after initial treatment, the question of the next regimen arises. In this situation, it is important to consider how long the previous treatment worked, what side effects it caused and how the patient feels now.

In September 2026, The New England Journal of Medicine published the results of the phase III TAISHAN-302 trial. It studied tambotatug pelitecan (also known as Tam-Peli and YL201) after progression on first-line platinum-based therapy. The new drug improved overall survival compared with topotecan. The publication reports a pre-planned interim analysis.

The trial in brief

The trial enrolled 451 patients with small-cell lung cancer after progression on initial treatment.
Tambotatug pelitecan was compared with topotecan, one of the chemotherapy drugs used at relapse.
The new treatment improved overall survival, time to progression and the rate of tumor shrinkage.
High-grade adverse events were less frequent, but treatment risks remained.

Key trial numbers

Patients were randomly assigned to two groups: tambotatug pelitecan (225 people) or topotecan (226 people). Second-line treatment after platinum-based therapy was evaluated.

Overall survival was longer with the new drug (median 13.3 vs. 9.4 months).
Progression-free survival also improved (median 7.4 vs. 2.8 months).
Confirmed tumor shrinkage was more frequent (objective response 59.1% vs. 9.7%).
Grade 3 or higher adverse events were less frequent (55.4% vs. 77.9%).

Medians describe the results of groups and cannot predict how long a particular person will live. Overall survival here was counted from randomization in the trial, not from diagnosis.

Why this matters for practice

Tambotatug pelitecan is an antibody–drug conjugate. The antibody recognizes the B7-H3 protein on tumor cells and helps deliver the anticancer component to them. This mechanism does not rule out effects on healthy tissues or side effects.

The practical value of TAISHAN-302 is that the benefit was shown in overall survival. This is an important result for discussing the future place of the drug in second-line treatment.

When choosing therapy after relapse, what still matters is the response to the previous regimen, the time until the disease returned, the extent of the tumor and the patient's general condition. That is why discussing the new data starts with a review of the treatment already received.

Commentary by Evgeny Ledin

This news is primarily relevant for patients with small-cell lung cancer whose disease has progressed after first-line treatment. At this point, it is important to understand which options for the next therapy are justified and what the patient will be able to tolerate.

For me, the most significant result is the one on overall survival. The trial gives serious grounds to consider tambotatug pelitecan as a potential new second-line option. At the same time, its place among other treatment methods still needs to be clarified.

I view these data with interest, but I would not turn them into a recommendation to change the regimen immediately. The trial criteria, the tolerability of treatment and the regulatory status of the drug have to be taken into account. The risk of inflammatory lung injury deserves particular attention.

My conclusion is this: when the disease progresses, it is worth reassessing the entire treatment situation and discussing the available options. Waiting for a new drug should not replace a timely decision about treatment that can be given now. But the results of the new drug are impressive.

Get a second opinion

When a second opinion is especially useful

The diagnosis has been confirmed, but after progression the choice of the next regimen remains unclear.
Different treatment options are being proposed, and you want to understand the reasoning behind each.
Previous therapy was accompanied by pronounced side effects.
You need to check whether the TAISHAN-302 results apply to a specific situation.
The available options are limited, and clinical trials need to be discussed.

What to prepare for the consultation

Histology or cytology report, immunohistochemistry results.
Discharge summaries with drug names, treatment dates and a description of side effects.
The latest and previous CT, MRI and PET-CT results, if performed; preferably together with the images.
Results of molecular testing and biomarker studies, if performed.
Recent complete blood count and blood chemistry.
A list of comorbidities and current medications.

Sources:

NEJM: Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy
PubMed: TAISHAN-302 publication, PMID 42734213
IASLC: TAISHAN-302 results at WCLC 2026
MediLink Therapeutics: Phase III results and acceptance of the marketing application in China
Roche: Information on the investigational drug, October 19, 2026
NCI: Small cell lung cancer treatment (PDQ)

Frequently Asked Questions

Is tambotatug pelitecan suitable for all patients with lung cancer?

No. TAISHAN-302 studied a specific situation — small-cell lung cancer after progression on first-line platinum-based therapy. The results do not apply to other types of lung cancer.

Is this already a new standard of care?

The trial provides grounds for changing approaches in the future. But positive phase III results, approval of the drug and its inclusion in routine practice are different stages. In the developers' current materials, the drug is still described as investigational.

Does current therapy need to be changed urgently?

The publication itself is not a reason to change treatment. If the disease is under control, the benefit and tolerability of the current regimen should be assessed. If progression is confirmed, the next approach is discussed with the treating oncologist.

Do 13.3 months mean a prognosis for a particular patient?

No. This is the median overall survival in the trial group. The individual course of the disease depends on many circumstances, and it is incorrect to apply this figure to an individual person.

Is the drug available in Russia?

Unfortunately, not yet. Even acceptance of a marketing application in another country does not mean that the drug is available in Russia.